3-(5-tert-butyl-2-hydroxyphenyl)-6,7-difluoro-3-(4-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one | 1491155-60-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(5-tert-butyl-2-hydroxyphenyl)-6,7-difluoro-3-(4-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one
• 英文别名: 3-(5-tert-butyl-2-hydroxyphenyl)-6,7-difluoro-3-(4-hydroxyphenyl)-1H-indol-2-one
• CAS: 1491155-60-2
• 化学式: C₂₄H₂₁F₂NO₃
• 分子量: 409.432
• InChiKey: WKHNBRHNWREYOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,3-二氟苯胺 在 盐酸 、 三溴化硼-二甲基硫醚 三溴甲基硫化硼 、 三氟甲磺酸 、 硫酸 、 盐酸羟胺 、 sodium sulfate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 3.5h， 生成 3-(5-tert-butyl-2-hydroxyphenyl)-6,7-difluoro-3-(4-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors

  摘要：

  The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the elF2.GTP.MettRNAlviet ternary complex assembly and 345-tert-butyl-2-hydroxypheny1}-3-phenyl-1,3-dihydro-2Hindol-2-one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low uM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.030

文献信息

• [EN] 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION<br/>[FR] OXINDOLES 3,3-DI-SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'INITIATION DE LA TRADUCTION
  申请人：HARVARD COLLEGE

  公开号：WO2014047437A1

  公开（公告）日：2014-03-27

  Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using diaryloxindole compounds are described.

  提供了用于抑制翻译的组合物和方法。描述了使用二苯氧吲哚化合物治疗（1）细胞增殖性疾病，（2）非增殖性退行性疾病，（3）病毒感染和/或（4）与病毒感染相关的疾病的组合物、方法和试剂盒。
• 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation
  申请人：President and Fellows of Harvard College

  公开号：US20160106711A1

  公开（公告）日：2016-04-21

  Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using diaryloxindole compounds are described.

  本发明提供了用于抑制翻译的组合物和方法。本发明还提供了使用二苯并呋喃衍生物治疗（1）细胞增殖性疾病，（2）非增殖性退行性疾病，（3）病毒感染和/或（4）与病毒感染相关的疾病的组合物、方法和试剂盒。
• Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors
  作者：Séverine Denoyelle、Ting Chen、Hongwei Yang、Limo Chen、Yingzhen Zhang、José A. Halperin、Bertal H. Aktas、Michael Chorev

  DOI：10.1016/j.ejmech.2013.08.030

  日期：2013.11

  The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the elF2.GTP.MettRNAlviet ternary complex assembly and 345-tert-butyl-2-hydroxypheny1}-3-phenyl-1,3-dihydro-2Hindol-2-one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low uM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer. (C) 2013 Elsevier Masson SAS. All rights reserved.